Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Pediatr Nephrol ; 39(7): 2161-2170, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38319465

RESUMEN

BACKGROUND: In the current study, longitudinal BP and lipid measurements were examined in a NEPTUNE cohort of children with newly diagnosed nephrotic syndrome (cNEPTUNE). We hypothesized that hypertensive BP and dyslipidemia would persist in children with nephrotic syndrome, regardless of steroid treatment response. METHODS: A multi-center longitudinal observational analysis of data obtained from children < 19 years of age with new onset nephrotic syndrome enrolled in the Nephrotic Syndrome Study Network (cNEPTUNE) was conducted. BP and lipid data were examined over time stratified by disease activity and steroid exposure. Generalized estimating equation regressions were used to find determinants of hypertensive BP and dyslipidemia. RESULTS: Among 122 children, the prevalence of hypertensive BP at any visit ranged from 17.4% to 57.4%, while dyslipidemia prevalence ranged from 40.0% to 96.2% over a median of 30 months of follow-up. Hypertensive BP was found in 46.2% (116/251) of study visits during active disease compared with 31.0% (84/271) of visits while in remission. Dyslipidemia was present in 88.2% (120/136) of study visits during active disease and in 66.0% (101/153) while in remission. Neither dyslipidemia nor hypertensive BP were significantly different with/without medication exposure (steroids and/or CNI). In regression analysis, male sex and urine protein:creatinine ratio (UPC) were significant determinants of hypertensive BP over time, while eGFR was found to be a determinant of dyslipidemia over time. CONCLUSIONS: Results demonstrate persistent hypertensive BPs and unfavorable lipid profiles in the cNEPTUNE cohort regardless of remission status or concurrent steroid or calcineurin inhibitor treatment.


Asunto(s)
Presión Sanguínea , Dislipidemias , Hipertensión , Síndrome Nefrótico , Humanos , Síndrome Nefrótico/orina , Síndrome Nefrótico/tratamiento farmacológico , Síndrome Nefrótico/complicaciones , Síndrome Nefrótico/epidemiología , Síndrome Nefrótico/sangre , Masculino , Niño , Femenino , Estudios Longitudinales , Hipertensión/epidemiología , Hipertensión/tratamiento farmacológico , Hipertensión/diagnóstico , Hipertensión/etiología , Preescolar , Dislipidemias/epidemiología , Dislipidemias/sangre , Adolescente , Lípidos/sangre , Prevalencia , Lactante
2.
J Pediatr ; 262: 113616, 2023 11.
Artículo en Inglés | MEDLINE | ID: mdl-37473987

RESUMEN

OBJECTIVE: To determine the association between dietary fiber intake and markers of cardiometabolic risk in adolescents, with blood pressure (BP) as the primary outcome of interest and secondary outcome measures including other established markers of childhood cardiometabolic risk, such as obesity, lipids, albuminuria, estimated glomerular filtration rate (eGFR), and uric acid. STUDY DESIGN: Dietary fiber intake was assessed by two 24-hour dietary recall interviews, which were averaged and corrected for body weight. Logistic and linear regression models were used to analyze the cross-sectional association between dietary fiber and cardiometabolic markers. Participants aged 13-17 years in the National Health and Nutritional Examination Survey 2009-2018 who completed a 24-hour dietary recall survey were included. Exclusion criteria included pregnancy, small for gestational age status, and history of major health comorbidities. RESULTS: In fully adjusted regression models, low dietary fiber intake was significantly associated with greater diastolic blood pressure (ß = -13.29; 95% CI, -20.66 to -5.93), body mass index z-score (ß = -0.91; 95% CI, -1.47 to -0.34), and uric acid (ß = -0.80; 95% CI, -1.44 to -0.16). CONCLUSIONS: The association found between low dietary fiber intake and poor childhood cardiometabolic risk markers indicate a need for prospective studies using fiber intake as a dietary intervention in childhood and as a tool for prevention of many chronic conditions.


Asunto(s)
Factores de Riesgo Cardiometabólico , Enfermedades Cardiovasculares , Humanos , Adolescente , Estados Unidos/epidemiología , Factores de Riesgo , Estudios Transversales , Estudios Prospectivos , Ácido Úrico , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Dieta/efectos adversos , Fibras de la Dieta
3.
Nutrients ; 12(10)2020 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-33023112

RESUMEN

The consumption of teff (Eragrostis tef), a gluten-free cereal grain, has increased due to its dense nutrient composition including complex carbohydrates, unsaturated fatty acids, trace minerals (especially Fe), and phytochemicals. This study utilized the clinically-validated Gallus gallus intra amniotic feeding model to assess the effects of intra-amniotic administration of teff extracts versus controls using seven groups: (1) non-injected; (2) 18Ω H2O injected; (3) 5% inulin; (4) teff extract 1%; (5) teff extract 2.5%; (6) teff extract 5%; and (7) teff extract 7.5%. The treatment groups were compared to each other and to controls. Our data demonstrated a significant improvement in hepatic iron (Fe) and zinc (Zn) concentration and LA:DGLA ratio without concomitant serum concentration changes, up-regulation of various Fe and Zn brush border membrane proteins, and beneficial morphological changes to duodenal villi and goblet cells. No significant taxonomic alterations were observed using 16S rRNA sequencing of the cecal microbiota. Several important bacterial metabolic pathways were differentially enriched in the teff group, likely due to teff's high relative fiber concentration, demonstrating an important bacterial-host interaction that contributed to improvements in the physiological status of Fe and Zn. Therefore, teff appeared to represent a promising staple food crop and should be further evaluated.


Asunto(s)
Eragrostis , Microbioma Gastrointestinal/efectos de los fármacos , Estado Nutricional/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Prebióticos/administración & dosificación , Semillas , Amnios , Animales , Ciego/microbiología , Pollos , Microbioma Gastrointestinal/genética , Inyecciones , Mucosa Intestinal/metabolismo , Hierro/sangre , Magnesio/sangre , Microvellosidades/efectos de los fármacos , ARN Ribosómico 16S/efectos de los fármacos , Oligoelementos/sangre , Zinc/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...